Literature DB >> 17956457

Urinary excretion of inositol phosphoglycan P-type in gestational diabetes mellitus.

M Scioscia1, S Kunjara, K Gumaa, P McLean, C H Rodeck, T W Rademacher.   

Abstract

OBJECTIVE: The mechanisms underlying insulin resistance during normal pregnancy, and its further exacerbation in pregnancies complicated by gestational diabetes mellitus (GDM), are generally unknown. Inositolphosphoglycan P-type (P-IPG), a putative second messenger of insulin, correlates with the degree of insulin resistance in diabetic subjects. An increase during normal pregnancy, in maternal and fetal compartments, has recently been reported.
METHODS: A cross-sectional study was carried out in 48 women with GDM and 23 healthy pregnant women. Urinary levels of P-IPG were assessed spectrophotometrically by the activation of pyruvate dehydrogenase phosphatase in urinary specimens and correlated with clinical parameters.
RESULTS: Urinary excretion of P-IPG was higher in GDM than in control women (312.1 +/- 151.0 vs. 210.6 +/- 82.7 nmol NADH/min/mg creatinine, P < 0.01) with values increasing throughout pregnancy in control subjects (r2 = 0.34, P < 0.01). P-IPG correlated with blood glucose levels (r(2) = 0.39, P < 0.01 for postprandial glycaemia and r2 = 0.18 P < 0.01 for mean glycaemia) and birthweight in the diabetic group (r2 = 0.14, P < 0.01).
CONCLUSIONS: Increased P-IPG urinary excretion occurs in GDM and positively correlates with blood glucose levels. P-IPG may play a role in maternal glycaemic control and, possibly, fetal growth in GDM.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17956457     DOI: 10.1111/j.1464-5491.2007.02267.x

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  8 in total

Review 1.  Inositols, Probiotics, and Gestational Diabetes: Clinical and Epigenetic Aspects.

Authors:  Ester Vitacolonna; Maria Masulli; Luisa Palmisano; Liborio Stuppia; Marica Franzago
Journal:  Nutrients       Date:  2022-04-08       Impact factor: 6.706

2.  Effect of dietary myo-inositol supplementation on the insulin resistance and the prevention of gestational diabetes mellitus: study protocol for a randomized controlled trial.

Authors:  George Asimakopoulos; Vasilios Pergialiotis; Eleni Anastasiou; Panagiotis Antsaklis; Mariana Theodora; Evangelia Vogiatzi; Aggela Kallergi; Michael Sindos; Dimitrios Loutradis; George Daskalakis
Journal:  Trials       Date:  2020-07-09       Impact factor: 2.279

Review 3.  Inositol and antioxidant supplementation: Safety and efficacy in pregnancy.

Authors:  Gloria Formoso; Maria P A Baldassarre; Federica Ginestra; Maria Assunta Carlucci; Ines Bucci; Agostino Consoli
Journal:  Diabetes Metab Res Rev       Date:  2019-04-10       Impact factor: 4.876

4.  Aberrant Autophagy Impacts Growth and Multicellular Development in a Dictyostelium Knockout Model of CLN5 Disease.

Authors:  Meagan D McLaren; Sabateeshan Mathavarajah; William D Kim; Shyong Q Yap; Robert J Huber
Journal:  Front Cell Dev Biol       Date:  2021-07-05

5.  myo-Inositol supplementation and onset of gestational diabetes mellitus in pregnant women with a family history of type 2 diabetes: a prospective, randomized, placebo-controlled study.

Authors:  Rosario D'Anna; Angela Scilipoti; Domenico Giordano; Carmela Caruso; Maria Letizia Cannata; Maria Lieta Interdonato; Francesco Corrado; Antonino Di Benedetto
Journal:  Diabetes Care       Date:  2013-01-22       Impact factor: 19.112

Review 6.  Metabolomics application in maternal-fetal medicine.

Authors:  Vassilios Fanos; Luigi Atzori; Karina Makarenko; Gian Benedetto Melis; Enrico Ferrazzi
Journal:  Biomed Res Int       Date:  2013-06-09       Impact factor: 3.411

7.  Can a dietary supplement prevent gestational diabetes mellitus?

Authors:  Donald R Coustan
Journal:  Diabetes Care       Date:  2013-04       Impact factor: 19.112

8.  The Inositol-3-Phosphate Synthase Biosynthetic Enzyme Has Distinct Catalytic and Metabolic Roles.

Authors:  Anna D Frej; Jonathan Clark; Caroline I Le Roy; Sergio Lilla; Peter A Thomason; Grant P Otto; Grant Churchill; Robert H Insall; Sandrine P Claus; Phillip Hawkins; Len Stephens; Robin S B Williams
Journal:  Mol Cell Biol       Date:  2016-05-02       Impact factor: 4.272

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.